Analysts expect Silo Pharma, Inc. to report revenue of 17,377.83 for Q3 23, against a range of 15,957.66 to 18,798.00. The most recent reported quarter, Q1 25, came in at 18,030.00.
| Metric | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 25 |
|---|---|---|---|---|---|
| Reported (Actual) | 18,000.00 | 18,000.00 | - | - | 18,030.00 |
| High Estimate | - | 20,635.55 | 18,798.00 | 19,458.47 | - |
| Low Estimate | - | 17,822.17 | 15,957.66 | 17,910.25 | - |
| Consensus Estimate | - | 19,228.86 | 17,377.83 | 18,684.36 | - |
Analysts expect Silo Pharma, Inc. to report earnings per share of -3.34 for Q3 23, against a range of -3.57 to -3.11. The most recent reported quarter, Q1 25, came in at -3.45.
| Metric | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 25 |
|---|---|---|---|---|---|
| Reported (Actual) | -4.35 | -4.80 | - | - | -3.45 |
| High Estimate | - | -4.18 | -3.11 | -2.93 | - |
| Low Estimate | - | -4.92 | -3.57 | -3.29 | - |
| Consensus Estimate | - | -4.55 | -3.34 | -3.11 | - |